This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Clinical Development Remove Compound Screening Remove Drugs Related Topics
In-Vivo In-Vitro Protein Pharma Companies Clinical Trials Licensing FDA Approval Trials Antibody Development More Related Topics >
article thumbnail

Informatics helps virtual biotech bring compound to clinical trial

Drug Discovery World

FEBRUARY 22, 2024

This article is sponsored by Collaborative Drug Discovery. Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. Users can also export data into Excel, so outgoing files can be password protected.

Clinical Trials 52
Clinical Trials Clinical Trials Trials In-Vivo 52
article thumbnail

Taking a new approach to tackle neurodegenerative diseases

Drug Discovery World

OCTOBER 4, 2022

New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).

Development 52
Development In-Vivo Compound Screening Clinical Development 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024